Preview

Онкоурология

Расширенный поиск

Комбинация пембролизумаб + акситиниб: новый «золотой стандарт» в 1-й линии при метастатическом светлоклеточном почечно-клеточном раке?

https://doi.org/10.17650/1726-9776-2020-16-3-29-37

Полный текст:

Аннотация

Стратегия лечения метастатического почечно-клеточного рака (мПКР) трансформировалась с появлением антиангиогенных препаратов, в частности ингибиторов тирозинкиназы (TKI), нацеленных на рецептор фактора роста эндотелия сосудов (VEGFR), и ингибиторов иммунных контрольных точек (ICI). Оба варианта лечения улучшили прогноз заболевания и изменили естественное течение мПКР. Клинические исследования были сосредоточены на оценке комбинированных схем, содержащих ICI и VEGFR-направленные TKI. Комбинация акситиниба с пембролизумабом (исследование KEYNOTE-426) показала лучшие результаты по сравнению с сунитинибом у пациентов с мПКР, не получавших ранее системную терапию. В настоящей статье обсуждены обоснование комбинации ICI и TKI на основе доклинических данных, а также клинические результаты, полученные при использовании комбинации акситиниба с пембролизумабом в 1-й линии терапии в клинических исследованиях при мПКР.

Об авторах

Р. А. Гафанов
Российский научный центр рентгенорадиологии Минздрава России
Россия

Гафанов Рустем Айратович.
117997 Москва, ул. Профсоюзная, 86.



А. Г. Дзидзария
Российский научный центр рентгенорадиологии Минздрава России
Россия
117997 Москва, ул. Профсоюзная, 86.


И. Б. Кравцов
Российский научный центр рентгенорадиологии Минздрава России
Россия
117997 Москва, ул. Профсоюзная, 86.


С. В. Фастовец
Российский научный центр рентгенорадиологии Минздрава России
Россия
117997 Москва, ул. Профсоюзная, 86.


Список литературы

1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. DOI: 10.3322/caac.21492.

2. Fisher R., Gore M., Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013;23(1):38-45. DOI: 10.1016/j.semcancer.2012.06.004.

3. Choueiri T.K., Motzer R.J. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376(4):354-66. DOI: 10.1056/NEJMra1601333.

4. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27 (Suppl. 5):v58-68. DOI: 10.1093/annonc/mdw328.

5. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603. DOI: 10.1038/nrc2442.

6. Curti B.D. Immunotherapy in advanced renal cancer - is cure possible? N Engl J Med 2018;378(14):1344-5. DOI: 10.1056/NEJMe1801682.

7. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(5):706-20. DOI: 10.1093/annonc/mdz056.

8. Hutson T.E. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011;16(Suppl 2):14-22. DOI: 10.1634/theoncologist.2011-S2-14.

9. Hutson T.E., Lesovoy V., Al-Shukri S. et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renalcell carcinoma: a randomized open-label phase 3 trial. Lancet 2013;14(13):1287-94. DOI: 10.1016/S1470-2045(13)70465-0.

10. Pedoeem A., Azoulay-Alfaguter I., Strazza M. et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014;153(1):145-52. DOI: 10.1016/j.clim.2014.04.010.

11. Wierecky J., Muller M.R., Wirths S. et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66(11):5910-8. DOI: 10.1158/0008-5472.CAN-05-3905.

12. Ahmadzadeh M., Johnson L.A., Heemskerk B. et al. Tumor antigenspecific CD8 T-cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114(8):1537-44. DOI: 10.1182/blood-2008-12-195792.

13. Finn O.J. Molecular origins of cancer: cancer immunology. N Engl J Med 2008;358:2704-15.

14. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331(6024): 1565-70. DOI: 10.1126/science.1203486.

15. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71. DOI: 10.1146/annurev-immunol-031210-101324.

16. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64. DOI: 10.1038/nrc3239.

17. Chen L., Flies D.B. Molecular mechanisms of T-cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13(4):227-42. DOI: 10.1038/ nri3405. Erratum in: Nat Rev Immunol 2013;13:542.

18. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467-77. DOI: 10.1038/nri2326.

19. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480(7378):480-9. DOI: 10.1038/nature10673.

20. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1-9.

21. Dion D.S., Krilov L., Cohen E. et al. Clinical Cancer advances 2016: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 2016;34(9):987-1011 DOI: 10.1200/JCO.2015.65.8427.

22. Larkin J.M.G., Tykodi S.S., Donskov F. et al. 949P-First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. Ann Oncol 2019;30(Suppl. 5): v381-2.

23. Nickerson M.L., Jaeger E., Shi Y. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14(15):4726-34. DOI: 10.1158/1078-0432.CCR-07-4921.

24. Barry R.E., Krek W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004;10(9):466-72. DOI: 10.1016/j.molmed.2004.07.008.

25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74. DOI: 10.1016/j.cell.2011.02.013.

26. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011;11(10):702-11. DOI: 10.1038/nri3064.

27. Khan K.A., Kerbel R.S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018;15(5):310-24. DOI: 10.1038/nrclinonc.2018.9.

28. Alfaro C., Suarez N., Gonzalez A. et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009;100(7):1111-9. DOI: 10.1038/sj.bjc.6604965.

29. Gabrilovich D.I., Chen H.L., Girgis K.R. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096-103. DOI: 10.1038/nm1096-1096.

30. Curiel T.J., Wei S., Dong H. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9(5):562-7. DOI: 10.1038/nm863.

31. Huang Y., Chen X., Dikov M.M. et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007;110(2):624-31. DOI: 10.1182/blood-2007-01-065714.

32. Ohm J.E., Gabrilovich D.I., Sempowski G.D. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101(12):4878-86. DOI: 10.1182/blood-2002-07-1956.

33. Gavalas N.G., Tsiatas M., Tsitsilonis O. et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012;107(11):1869-75. DOI: 10.1038/bjc.2012.468.

34. Voron T., Colussi O., Marcheteau E. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015;212(2):139-48. DOI: 10.1084/jem.20140559.

35. Ruf M., Moch H., Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 2016;139(2): 396-403. DOI: 10.1002/ijc.30077.

36. Adotevi O., Pere H., Ravel P. et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010;33(9):991-8. DOI: 10.1097/CJI.0b013e3181f4c208.

37. Huang H., Langenkamp E., Georganaki M. et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-KB-induced endothelial activation. FASEB J 2015;29(1): 227-38. DOI: 10.1096/fj.14-250985.

38. Griffioen A.W., Damen C.A., Martinotti S. et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996;56(5):1111-7.

39. Motz G.T., Santoro S.P., Wang L.P. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20(6):607-15. DOI: 10.1038/nm.3541.

40. Pittet C.L., Newcombe J., Prat A. et al. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011;8:155. DOI: 10.1186/1742-2094-8-155.

41. Seaman S., Stevens J., Yang M.Y. et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11(6):539-54. DOI: 10.1016/j.ccr.2007.04.017.

42. Palazon A., Aragones J., Morales-Kastresana A. et al. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012;18(5):1207-13. DOI: 10.1158/1078-0432.CCR-11-1591.

43. Movahedi K., Laoui D., Gysemans C. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010;70(14):5728-39. DOI: 10.1158/0008-5472.CAN-09-4672.

44. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012.

45. Osada T., Chong G., Tansik R. et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57(8):1115-24. DOI: 10.1007/s00262-007-0441-x.

46. Kusmartsev S., Eruslanov E., Kubler H. et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008;181(1):346-53. DOI: 10.4049/jimmunol.181.1.346.

47. Huang Y., Goel S., Duda D.G. et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013;73(10):2943-8. DOI: 10.1158/0008-5472.CAN-12-4354.

48. Yasuda S., Sho M., Yamato I. et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013;172(3):500-6. DOI: 10.1111/cei.12069.

49. Tian L., Goldstein A., Wang H. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017;544(7649):250-4. DOI: 10.1038/nature21724.

50. Atkins M.B., Plimack E.R., Puzanov I. et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 2018;19(3):405-15. DOI: 10.1016/S1470-2045(18)30081-0.

51. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116-27. DOI: 10.1056/NEJMoa1816714.

52. Plimack E., Rini B., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. J Clin Oncol 2020;38(suppl; abstr 5001).


Для цитирования:


Гафанов Р.А., Дзидзария А.Г., Кравцов И.Б., Фастовец С.В. Комбинация пембролизумаб + акситиниб: новый «золотой стандарт» в 1-й линии при метастатическом светлоклеточном почечно-клеточном раке? Онкоурология. 2020;16(3):29-37. https://doi.org/10.17650/1726-9776-2020-16-3-29-37

For citation:


Gafanov R.A., Dzidzaria A.G., Kravtsov I.B., Fastovets S.V. Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma? Cancer Urology. 2020;16(3):29-37. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-3-29-37

Просмотров: 33


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X